Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19.8M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
2.36M
-
Shares change
-
+1.74M
-
Total reported value, excl. options
-
$6.05M
-
Value change
-
+$4.55M
-
Number of buys
-
22
-
Number of sells
-
-10
-
Price
-
$2.56
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2025
42 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.36M shares
of 19.8M outstanding shares and own 11.93% of the company stock.
Largest 10 shareholders include MILLENNIUM MANAGEMENT LLC (1.03M shares), OAKTREE CAPITAL MANAGEMENT LP (241K shares), FMR LLC (199K shares), VANGUARD GROUP INC (192K shares), GEODE CAPITAL MANAGEMENT, LLC (125K shares), XTX Topco Ltd (113K shares), BlackRock, Inc. (84.3K shares), STATE STREET CORP (52.7K shares), UBS Group AG (43.5K shares), and Oaktree Fund Advisors, LLC (42.9K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.